Table 1. Retrospective studies of cytoreductive surgery in patients with recurrent or metastatic GIST on TKI therapy.
| Study | Month/year of surgery | N | TKI at surgery imatinib/sunitinib | Median [range] preoperative TKI duration (months) | Complete resection % by disease status at time of surgery | Median follow-up from time of surgery (months) | Median PFS by disease status at time of surgery (months) | 2-year PFS by disease status at time of surgery (%) | Median OS by disease status at time of surgery (months) | 2-year OS by disease status at time of surgery (%) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| O | R/S | LR | SR | O | R/S | LR | SR | O | R/S | LR | SR | O | R/S | LR | SR | O | R/S | LR | SR | |||||||||
| Raut, 2006 (24) | Mar 2002–Nov 2004 | 69 | 45/21 | – | – | 78 | 25 | 7 | 14.6 [0.5–36] | – | NR | 7.7 | 2.9 | – | 58 | 18 | 0 | – | NR | 29.8 | 5.6 | – | 90 | 72 | 0 | |||
| DeMatteo, 2007 (25) | Jan 2001–Jul 2005 | 40 | 37/3 | 15 [1–48] | 62.5 | 85 | 46.2 | 28.6 | 15 [6–46] | 15 | NR | 12 | 3 | 39 | 61 | 24 | 0 | 39 | NR | 19 | 11 | 62 | 100 | 36 | 0 | |||
| Gronchi, 2007 (26) | Jan 2001–Jun 2005 | 38 | 38/0 | >12 | 81.5 | 88.9 | 50 | 100 | 29 [6–36] | – | NR | 3 | – | – | 69 | 0 | 0 | – | NR | NR | – | – | 100 | 60 | 0 | |||
| Sym, 2008 (27) | Jun 2001–Jan 2006 | 26 | 26/0 | 18.1 [2.2–53] | 62 | 79 | 33 | 14 | 25.7 [4.3–59] | – | 21.8 | 5.1 | 3.3 | – | 65 | 0 | 0 | – | NR | 22.5 | 23.5 | – | 96 | 68 | 38 | |||
| Yeh, 2010 (28) | Jan 2001–May 2009 | 35 | 35/0 | >14 | 18.4 | 42.9 | 4.8 | 0 | 37 [7.7–75] | – | NR | 8.3 | 2 | – | 59.4 | 35.9 | 0 | – | NR | NR | – | – | 69.6 | 48.4 | – | |||
| Mussi, 2010 (29) | Jul 2002–Oct 2007 | 80 | 80/0 | >15 | – | 88 | 45 | – | >13 [0–76] | – | NR | 8 | – | – | 64.4 | 9.7 | – | – | NR | NR | – | – | 82.9 | 67.6 | – | |||
| Park, 2014 (30) | Jan 2001–Jun 2010 | 42 | 42/0 | 19.1 [7.2–87] | 62 | 62 | – | – | 58.9 [15–129] | 87.7 | 87.7 | – | – | – | – | – | – | NR | NR | – | – | – | – | – | – | |||
| Rubió-Casadevall, 2015 (31) | Jan 2001–Dec 2008 | 27 | 27/0 | 49 | – | 70.4 | 25 | – | 56.6 | 73.4 | 73.4 | – | – | – | – | – | – | 87.6 | 87.6 | – | – | – | – | – | – | |||
| Fairweather, 2017 (32) | Jan 2001–Dec 2014 | 400 | 234/93 | 20 [8–39] | 34 | – | – | – | 33.6 [9.5–45] | 11 | 31/19 | 10 | 5 | – | – | – | – | 81 | NR/110 | 54 | 26 | – | – | – | – | |||
| 234 | 234/0 | 16 [7–36] | – | – | – | – | – | 16 | 36/30 | 11 | 6 | – | – | – | – | 105 | NR/110 | 59 | 24 | – | – | – | – | |||||
| 93 | 0/93 | 25 [12–39] | – | – | – | – | – | 7 | – | – | – | – | – | – | – | 48 | – | – | – | – | – | – | – | |||||
| Raut, 2010 (33) | Feb 2003–Feb 2008 | 50 | 0/50 | 6.7 [1.9–48] | 50 | 40 | 64 | 39 | 15.2 [1.0–54] | 5.8 | 11 | 6.1 | 4.1 | – | – | – | – | 16.4 | NR | 18.5 | 8.9 | – | – | – | – | |||
| Yeh, 2017 (34) | Aug 2001–Dec 2014 | 26 | 0/26 | 6.2 [1–41] | – | – | – | – | 15.2 [1.0–54] | 5.2 | – | 5.2 | – | – | – | – | – | 20 | – | 20 | – | – | – | – | – | |||
TKI, tyrosine kinase inhibitor; GIST, gastrointestinal stromal tumor; O, overall; R/S, response/stable; LR, limited resistance; SR, systemic resistance.